The resveratrol analog HS-1793 enhances radiosensitivity of mouse-derived breast cancer cells under hypoxic conditions

Choi,Yoo Jin; Heo,Kyu; Park,Hee Sung; Yang,Kwang Mo; Jeong,Min Ho

doi:10.3892/ijo.2016.3647

The resveratrol analog HS-1793 enhances radiosensitivity of mouse-derived breast cancer cells under hypoxic conditions

Authors:
- Yoo Jin Choi
- Kyu Heo
- Hee Sung Park
- Kwang Mo Yang
- Min Ho Jeong
View Affiliations

Affiliations: Department of Research Center, Dong Nam Institute of Radiological and Medical Sciences, Busan 619-953, Republic of Korea, Department of Microbiology, Dong-A University College of Medicine, Busan 602-714, Republic of Korea
Published online on: August 3, 2016 https://doi.org/10.3892/ijo.2016.3647
Pages: 1479-1488

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor hypoxia is associated with treatment resistance, cell proliferation, and metastatic potential, all of which contribute to a poor prognosis. Resveratrol [RES (trans-3,4',5-trihydroxystilbene)], a naturally occurring polyphenol, is enriched in grapes and red wine. This study investigated whether the resveratrol analog HS-1793 modulates the hypoxic status and the level of perfusion in mouse breast cancer FM3A cells. Our data show that HS-1793 decreased the levels of hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor protein under hypoxic conditions in FM3A cells. HS-1793 improved perfusion and hypoxic status in tumor tissues and inhibited angiogenesis through HIF-1α suppression in mice. Moreover, HS-1793 inhibited hypoxia-induced cancer stem cell properties and enhanced ionizing radiation-induced apoptosis in hypoxic FM3A cells. Collectively, the resveratrol analog HS-1793 might act as a potent radiosensitizer and be a useful adjuvant agent against radiotherapy-resistant hypoxic cells in solid tumors.

View Figures

View References

1	Keith B and Simon MC: Hypoxia-inducible factors, stem cells, and cancer. Cell. 129:465–472. 2007. View Article : Google Scholar : PubMed/NCBI
2	Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
3	Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995. View Article : Google Scholar : PubMed/NCBI
4	Rich J, Borton A and Wang X: Transforming growth factor-beta signaling in cancer. Microsc Res Tech. 52:363–373. 2001. View Article : Google Scholar : PubMed/NCBI
5	Sánchez-Elsner T, Botella LM, Velasco B, Corbí A, Attisano L and Bernabéu C: Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem. 276:38527–38535. 2001. View Article : Google Scholar : PubMed/NCBI
6	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
7	Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, et al: Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 122:947–956. 2005. View Article : Google Scholar : PubMed/NCBI
8	Yu F, Li J, Chen H, Fu J, Ray S, Huang S, Zheng H and Ai W: Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene. 30:2161–2172. 2011. View Article : Google Scholar : PubMed/NCBI
9	Baumann M, Krause M and Hill R: Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer. 8:545–554. 2008. View Article : Google Scholar : PubMed/NCBI
10	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
11	DeSantis C, Siegel R and Jemal A: Breast cancer facts and figures 2007–2008. Amer Can Soc. 1–32. 2008.
12	Limer JL and Speirs V: Phytooestrogens and breast cancer chemoprevention. Breast Cancer Res. 6:119–127. 2004. View Article : Google Scholar :
13	Privat C, Telo JP, Bernardes-Genisson V, Vieira A, Souchard JP and Nepveu F: Antioxidant properties of trans-epsilon-viniferin as compared to stilbene derivatives in aqueous and nonaqueous media. J Agric Food Chem. 50:1213–1217. 2002. View Article : Google Scholar : PubMed/NCBI
14	Kong AN, Yu R, Hebbar V, Chen C, Owuor E, Hu R, Ee R and Mandlekar S: Signal transduction events elicited by cancer prevention compounds. Mutat Res. 480–481:231–241. 2001. View Article : Google Scholar
15	Jeong SH, Jo WS, Song S, Suh H, Seol SY, Leem SH, Kwon TK and Yoo YH: A novel resveratrol derivative, HS1793, overcomes the resistance conferred by Bcl-2 in human leukemic U937 cells. Biochem Pharmacol. 77:1337–1347. 2009. View Article : Google Scholar : PubMed/NCBI
16	Raleigh JA, Miller GG, Franko AJ, Koch CJ, Fuciarelli AF and Kelly DA: Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours. Br J Cancer. 56:395–400. 1987. View Article : Google Scholar : PubMed/NCBI
17	Rijken PF, Bernsen HJ, Peters JP, Hodgkiss RJ, Raleigh JA and van der Kogel AJ: Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: A quantitative multi-parameter analysis. Int J Radiat Oncol Biol Phys. 48:571–582. 2000. View Article : Google Scholar : PubMed/NCBI
18	Raleigh JA, Franko AJ, Treiber EO, Lunt JA and Allen PS: Covalent binding of a fluorinated 2-nitroimidazole to EMT-6 tumors in Balb/C mice: Detection by F-19 nuclear magnetic resonance at 2.35 T. Int J Radiat Oncol Biol Phys. 12:1243–1245. 1986. View Article : Google Scholar : PubMed/NCBI
19	Bernsen HJ, Rijken PF, Hagemeier NE and van der Kogel AJ: A quantitative analysis of vascularization and perfusion of human glioma xenografts at different implantation sites. Microvasc Res. 57:244–257. 1999. View Article : Google Scholar : PubMed/NCBI
20	Durand RE and Raleigh JA: Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res. 58:3547–3550. 1998.PubMed/NCBI
21	Garvin S, Ollinger K and Dabrosin C: Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 231:113–122. 2006. View Article : Google Scholar
22	Jeong MH, Yang KM, Choi YJ, Kim SD, Yoo YH, Seo SY, Lee SH, Ryu SR, Lee CM, Suh H, et al: Resveratrol analog, HS-1793 enhance anti-tumor immunity by reducing the CD4⁺CD25⁺ regulatory T cells in FM3A tumor bearing mice. Int Immunopharmacol. 14:328–333. 2012. View Article : Google Scholar : PubMed/NCBI
23	Jögi A, Øra I, Nilsson H, Lindeheim A, Makino Y, Poellinger L, Axelson H and Påhlman S: Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci USA. 99:7021–7026. 2002. View Article : Google Scholar : PubMed/NCBI
24	Tavaluc RT, Hart LS, Dicker DT and El-Deiry WS: Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. Cell Cycle. 6:2554–2562. 2007. View Article : Google Scholar : PubMed/NCBI
25	Giuntoli S, Rovida E, Gozzini A, Barbetti V, Cipolleschi MG, Olivotto M and Dello Sbarba P: Severe hypoxia defines heterogeneity and selects highly immature progenitors within clonal erythroleukemia cells. Stem Cells. 25:1119–1125. 2007. View Article : Google Scholar : PubMed/NCBI
26	Das B, Tsuchida R, Malkin D, Koren G, Baruchel S and Yeger H: Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells. 26:1818–1830. 2008. View Article : Google Scholar : PubMed/NCBI
27	McCord AM, Jamal M, Shankavaram UT, Lang FF, Camphausen K and Tofilon PJ: Physiologic oxygen concentration enhances the stem-like properties of CD133⁺ human glioblastoma cells in vitro. Mol Cancer Res. 7:489–497. 2009. View Article : Google Scholar : PubMed/NCBI
28	Vaupel P: The role of hypoxia-induced factors in tumor progression. Oncologist. 9(Suppl 5): 10–17. 2004. View Article : Google Scholar : PubMed/NCBI
29	Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM and Johnson RS: Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 60:4010–4015. 2000.PubMed/NCBI
30	Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR and Dewhirst MW: Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:941–943. 1996.PubMed/NCBI
31	Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003. View Article : Google Scholar : PubMed/NCBI
32	Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW and Semenza GL: Expression of hypoxia-inducible factor 1alpha in brain tumors: Association with angiogenesis, invasion, and progression. Cancer. 88:2606–2618. 2000. View Article : Google Scholar : PubMed/NCBI
33	Brown NS, Jones A, Fujiyama C, Harris AL and Bicknell R: Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res. 60:6298–6302. 2000.PubMed/NCBI
34	Benckert C, Jonas S, Cramer T, Von Marschall Z, Schäfer G, Peters M, Wagner K, Radke C, Wiedenmann B, Neuhaus P, et al: Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res. 63:1083–1092. 2003.PubMed/NCBI
35	Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003. View Article : Google Scholar : PubMed/NCBI
36	Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J and Le AD: Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther. 4:1465–1474. 2005. View Article : Google Scholar : PubMed/NCBI
37	Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG and Wicha MS: Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA. 109:2784–2789. 2012. View Article : Google Scholar : PubMed/NCBI
38	Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen LC, Smith KD, Cushing RC and Seagroves TN: Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res. 14:R62012. View Article : Google Scholar
39	Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, et al: Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 15:501–513. 2009. View Article : Google Scholar : PubMed/NCBI
40	Rosen EM, Fan S, Rockwell S and Goldberg ID: The molecular and cellular basis of radiosensitivity: Implications for understanding how normal tissues and tumors respond to therapeutic radiation. Cancer Invest. 17:56–72. 1999. View Article : Google Scholar
41	Camphausen K and Tofilon PJ: Combining radiation and molecular targeting in cancer therapy. Cancer Biol Ther. 3:247–250. 2004. View Article : Google Scholar : PubMed/NCBI
42	Moeller BJ, Cao Y, Li CY and Dewhirst MW: Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. Cancer Cell. 5:429–441. 2004. View Article : Google Scholar : PubMed/NCBI
43	Dewhirst MW, Cao Y and Moeller B: Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 8:425–437. 2008. View Article : Google Scholar : PubMed/NCBI